Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01302132
NCT01302132
Completed
Phase 1

An Open Label Study to Evaluate the Pharmacokinetics of ASP1941 After a Single Oral Dose of 14C-labeled ASP1941 in Healthy Male Subjects

Astellas Pharma Inc0 sites6 target enrollmentMay 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy Subjects
DrugsASP1941

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy Subjects
Sponsor
Astellas Pharma Inc
Enrollment
6
Primary Endpoint
Pharmacokinetics of ASP1941 to evaluate metabolism and excretion
Status
Completed
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This study investigates the pharmacokinetics, in particular the routes and extent of metabolism and excretion, of ASP1941 after a single oral dose.

Registry
clinicaltrials.gov
Start Date
May 2008
End Date
October 2008
Last Updated
15 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Body weight between 60-100kg, BMI between 18.5-30 kg/m2, inclusive

Exclusion Criteria

  • •Pulse \<40 or \>90 bpm; Systolic Blood Pressure \> 140 mmHg; Diastolic Blood Pressure \>90 mmHg

Outcomes

Primary Outcomes

Pharmacokinetics of ASP1941 to evaluate metabolism and excretion

Time Frame: up to 216 hours

Secondary Outcomes

  • Identification of metabolic profile of ASP1941(up to 216 hours)

Similar Trials

Completed
Phase 1
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic FunctionHepatic Impairment
NCT01863784Janssen Research & Development, LLC28
Completed
Phase 1
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisEnd-Stage Renal Disease
NCT02289703Janssen Research & Development, LLC16
Active, not recruiting
Phase 1
A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term pai
EUCTR2019-000205-77-PLGrünenthal GmbH15
Not yet recruiting
Not Applicable
PK of intra-vaginal oxybutyni
NL-OMON20539iGalli BV8
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic ImpairmentHepatic Impairment
NCT01767948Janssen Research & Development, LLC30